Results 271 to 280 of about 346,103 (330)

Concurrent Bone Marrow Acute Undifferentiated Leukemia and Mediastinal T-Lymphoblastic Lymphoma With Identical <i>SET::NUP214</i> Fusion and <i>PHF6</i> and <i>EZH2</i> Mutations. [PDF]

EJHaem
Wei Q, Jelloul FZ, Wang SA, Tang G, Li S, Lin P, Loghavi S, Wang HY, Medeiros LJ, Xu J.   +9 more
europepmc   +1 more source

Chronic myeloid leukemia in India

Indian Journal of Medical and Paediatric Oncology, 2013
openaire   +3 more sources

Evaluating the role of astragalus polysaccharide in modulating immune infiltration and enhancing prognostic biomarkers in pediatric acute myeloid leukemia. [PDF]

Front Pharmacol
He MH, Zhang XH, Zhang JH, Pan J, Yang C.   +4 more
europepmc   +1 more source

The adult HNRNPH1::ERG positive acute myeloid leukemia with clear lower remission and worse prognosis: A case report and review of the literature. [PDF]

Medicine (Baltimore)
Lu Y, Wei R, Li J, Xu L.
europepmc   +1 more source

[Corrigendum] Use of methylation profiling to identify significant differentially methylated genes in bone marrow mesenchymal stromal cells from acute myeloid leukemia. [PDF]

Int J Mol Med
Huang J, Liu Z, Sun Y, Zhong Q, Xu L, Ou R, Li C, Chen R, Yao M, Zhang Q, Liu S.   +10 more
europepmc   +1 more source

Mechanisms of enhancer‐driven oncogene activation

International Journal of Cancer, EarlyView.
Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend, Ruud Delwel, Dorien Pastoors   +2 more
wiley   +1 more source

Prospective, Randomized, Comparative Study of Myeloablative Fludarabine/Busulfan and Fludarabine/Busulfan/Total Body Irradiation Conditioning in Myeloid Diseases. [PDF]

Cancers (Basel)
Suh HC, Rowley SD, Kaur S, Lukasik B, McKiernan P, Boonstra M, Baker M, DiLorenzo M, Skarbnik A, Voss J, Hampson A, DeAgresta B, Boylan B, Nyirenda T, Vesole DH, Donato ML.   +15 more
europepmc   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

Leukemia Cutis in a Patient with Acute Myeloid Leukemia Undergoing Azacitidine-Venetoclax: Case Presentation and Review of the Literature. [PDF]

Mediterr J Hematol Infect Dis
Buzzatti E, Mauro C, Botti C, Presicci R, Paterno G, Palmieri R, Gurnari C, Mallegni F, Meddi E, Moretti F, Cardillo L, Mezzanotte V, Taka K, De Marchi L, Maurillo L, Buccisano F, Venditti A, Del Principe MI.   +17 more
europepmc   +1 more source

Enhancer‐dependent gene regulation in space, time, and malignancies

International Journal of Cancer, EarlyView.
Abstract Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.
Belinda Blum, Victoria Dachtler, Angelika Feldmann   +2 more
wiley   +1 more source